Pharmacokinetic Optimisation of Dopamine Receptor Agonist Therapy for Parkinson??s Disease

This publication has 122 references indexed in Scilit:

• An overnight switch to ropinirole therapy in patients with Parkinson's disease
  Journal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1999
• A new sublingual formulation of apomorphine in the treatment of patients with Parkinson's disease
  Movement Disorders, 1996
• A “combined” levodopa test as a useful method for evaluating the efficacy of dopamine agonists: Application to pergolide and bromocriptine
  Movement Disorders, 1995
• Clinical classification of dopaminergic effects in parkinsonism
  Neurochemistry International, 1992
• The effect of food and metoclopramide on the pharmacokinetics and side effects of bromocriptine
  European Journal of Drug Metabolism and Pharmacokinetics, 1991
• Failure of oral administration of single rising doses of bromocriptine to produce acute anti-Parkinsonian effects.
  Journal of Neurology, Neurosurgery & Psychiatry, 1991
• Pergolide: A dopamine agonist at both D1 and D2 receptors
  Life Sciences, 1991
• Uneven Pattern of Dopamine Loss in the Striatum of Patients with Idiopathic Parkinson's Disease
  New England Journal of Medicine, 1988
• THE EFFECT OF BROMOCRIPTINE ON RAT STRIATAL ADENYLATE CYCLASE AND RAT BRAIN MONOAMINE METABOLISM
  Journal of Neurochemistry, 1978
• Effects of bromocriptine on central dopaminergic receptors
  Life Sciences, 1976